PDCD1 and neoplasm: In addition, Łuksza et al. described a neoantigen fitness model based on the likelihood of neoantigen presentation by HLA molecules and subsequent T cell recognition, which is able to predict clinical outcome of anti-PD-1 antibody-treated tumor patients [80].